GNLX
Genelux Corporation
NASDAQ · Healthcare · Biotechnology · US
$2.44
−3.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.0K | 8.0K | 8.0K | 170.0K | 11.1M |
| Cost of Revenue | 149.0K | 574.0K | 903.0K | 1.0M | 968.0K |
| Gross Profit | (141.0K) | (566.0K) | (895.0K) | (848.0K) | 10.1M |
| Operating Expenses | |||||
| R&D Expense | 22.1M | 19.9M | 19.0M | 12.8M | 9.1M |
| SG&A Expense | 13.5M | 13.4M | 12.7M | 11.6M | 5.0M |
| General & Admin Expense | 13.5M | 13.4M | 12.7M | 11.6M | 5.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (148.0K) | (574.0K) | (903.0K) | (1.0M) | (968.0K) |
| Total Operating Expenses | 35.5M | 32.6M | 30.8M | 23.3M | 13.1M |
| Cost and Expenses | 35.6M | 33.2M | 31.7M | 24.3M | 14.1M |
| Operating Income (EBIT) | (35.6M) | (33.2M) | (31.7M) | (24.2M) | (3.0M) |
| Non-Operating | |||||
| Interest Income | 1.8M | 1.1M | 1.5M | 244.0K | — |
| Interest Expense | — | — | — | 4.0M | 1.4M |
| Net Interest Income | 1.8M | 1.1M | 1.5M | (3.7M) | (1.4M) |
| Other Non-Op Income/Expense | 1.8M | 1.1M | 1.8M | (4.1M) | (1.1M) |
| Non-Operating Income (excl Interest) | (1.1M) | (1.1M) | (1.8M) | 3.3M | (314.0K) |
| EBT (Pre-Tax Income) | (33.8M) | (32.1M) | (29.9M) | (28.3M) | (4.1M) |
| Income Tax Expense | — | — | — | — | 1.1M |
| Bottom Line | |||||
| Net Income | (33.8M) | (32.1M) | (29.9M) | (28.3M) | (5.2M) |
| Earnings from Cont. Ops | (33.8M) | (32.1M) | (29.9M) | (28.3M) | (5.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (33.8M) | (32.1M) | (29.9M) | (28.3M) | (5.2M) |
| Per Share | |||||
| Basic EPS | ($0.89) | ($0.86) | ($0.95) | ($1.16) | ($0.21) |
| Diluted EPS | ($0.89) | ($0.86) | ($0.95) | ($1.16) | ($0.21) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.01 | $0.45 |
| Shares | |||||
| Basic Shares Outstanding | 45.0M | 37.2M | 31.5M | 24.4M | 24.6M |
| Diluted Shares Outstanding | 45.0M | 37.2M | 31.5M | 24.4M | 24.6M |
| Profitability Metrics | |||||
| EBITDA | (34.2M) | (31.6M) | (29.0M) | (26.5M) | (1.7M) |
| D&A | 348.0K | 574.0K | 903.0K | 1.0M | 968.0K |
| EBIT | (34.5M) | (32.1M) | (29.9M) | (27.5M) | (2.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026